{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:30:47Z","timestamp":1761489047528,"version":"build-2065373602"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Surgeon"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.surge.2022.09.004","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T07:52:17Z","timestamp":1666770737000},"page":"e126-e132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The translational implications of the science behind the overactive bladder and the role of OnabotulinumtoxinA"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1495-6455","authenticated-orcid":false,"given":"Nawal","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Shamim","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachin","family":"Malde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun","family":"Sahai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prokar","family":"Dasgupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.surge.2022.09.004_bib1","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","article-title":"Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction","volume":"108","author":"Irwin","year":"2011","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.surge.2022.09.004_bib2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/nau.20737","article-title":"Reviewing the ICS 2002 terminology report: the ongoing debate","volume":"28","author":"Abrams","year":"2009","journal-title":"Neurourol Urodyn"},{"issue":"12","key":"10.1016\/j.surge.2022.09.004_bib3","doi-asserted-by":"crossref","first-page":"823","DOI":"10.4140\/TCP.n.2014.823","article-title":"Mirabegron: a Beta-3 agonist for overactive bladder","volume":"29","author":"Bragg","year":"2014","journal-title":"Consult Pharm"},{"issue":"11","key":"10.1016\/j.surge.2022.09.004_bib4","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1111\/j.1464-410X.2012.11023.x","article-title":"Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience","volume":"110","author":"Wagg","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.surge.2022.09.004_bib6","first-page":"641","article-title":"Zur operation der angebarenen blaben-Spalte","volume":"20","author":"Von Mikulicz","year":"1889","journal-title":"Zentralbl Chir"},{"issue":"6","key":"10.1016\/j.surge.2022.09.004_bib7","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1464-410X.1982.tb13626.x","article-title":"The treatment of adult enuresis and urge incontinence by enterocystoplasty","volume":"54","author":"Bramble","year":"1982","journal-title":"Br J Urol"},{"issue":"4","key":"10.1016\/j.surge.2022.09.004_bib8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s003450050061","article-title":"Gastrocystoplasty: is there a consensus?","volume":"16","author":"Kurzrock","year":"1998","journal-title":"World J Urol"},{"issue":"6","key":"10.1016\/j.surge.2022.09.004_bib9","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0022-5347(17)42038-6","article-title":"Electrical stimulation in the clinical management of the neurogenic bladder","volume":"140","author":"Tanagho","year":"1988","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.surge.2022.09.004_bib10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.juro.2017.07.010","article-title":"Five-year followup results of a prospective, multicenter study of patients with overactive bladder treated with sacral neuromodulation","volume":"199","author":"Siegel","year":"2018","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.surge.2022.09.004_bib11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/1756287218756082","article-title":"Electrical neuromodulation in the management of lower urinary tract dysfunction: evidence, experience and future prospects","volume":"10","author":"Abello","year":"2018","journal-title":"Ther Adv Urol"},{"issue":"1","key":"10.1016\/j.surge.2022.09.004_bib12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1113\/jphysiol.1969.sp008683","article-title":"Reflexes to sacral parasympathetic neurones concerned with micturition in the cat","volume":"200","author":"de Groat","year":"1969","journal-title":"J Physiol (Camb)"},{"issue":"5 Suppl 1","key":"10.1016\/j.surge.2022.09.004_bib13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)01544-3","article-title":"Bladder afferents and their role in the overactive bladder","volume":"59","author":"Fowler","year":"2002","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.surge.2022.09.004_bib14","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1464-410X.2012.11672.x","article-title":"Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)?","volume":"111","author":"Seth","year":"2013","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.surge.2022.09.004_bib15","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1046\/j.1464-410X.1997.00424.x","article-title":"Chillies: from antiquity to urology","volume":"80","author":"Dasgupta","year":"1997","journal-title":"Br J Urol"},{"issue":"1","key":"10.1016\/j.surge.2022.09.004_bib16","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0022-5347(17)38701-3","article-title":"Cystometric evidence that capsaicin-sensitive nerves modulate the afferent branch of micturition reflex in humans","volume":"142","author":"Maggi","year":"1989","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.surge.2022.09.004_bib17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/jnnp.57.2.169","article-title":"Intravesical capsaicin for treatment of detrusor hyperreflexia","volume":"57","author":"Fowler","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.surge.2022.09.004_bib18","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1046\/j.1464-410x.2000.00427.x","article-title":"The effect of intravesical capsaicin on the suburothelial innervation in patients with detrusor hyper-reflexia","volume":"85","author":"Dasgupta","year":"2000","journal-title":"BJU Int"},{"issue":"15","key":"10.1016\/j.surge.2022.09.004_bib19","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1021\/jm960139d","article-title":"Similarities and differences in the structure-activity relationships of capsaicin and resiniferatoxin analogues","volume":"39","author":"Walpole","year":"1996","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.surge.2022.09.004_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/00005392-199907000-00002","article-title":"Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder","volume":"162","author":"Chancellor","year":"1999","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.surge.2022.09.004_bib21","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s001050051206","article-title":"Botulinumtoxin: vom Gift zum Medikament. Ein historischer R\u00fcckblick [Botulinum toxin: from poison to drug. A historical review]","volume":"51","author":"Kreyden","year":"2000","journal-title":"Hautarzt"},{"issue":"4","key":"10.1016\/j.surge.2022.09.004_bib22","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/clinids\/1.4.701","volume":"1","author":"van Ermengem","year":"1979","journal-title":"Rev Infect Dis"},{"issue":"7","key":"10.1016\/j.surge.2022.09.004_bib23","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1212\/WNL.53.7.1439","article-title":"Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia","volume":"53","author":"Brashear","year":"1999","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.surge.2022.09.004_bib24","first-page":"924","article-title":"Pharmacologic weakening of extraocular muscles","volume":"12","author":"Scott","year":"1973","journal-title":"Invest Ophthalmol"},{"issue":"5","key":"10.1016\/j.surge.2022.09.004_bib25","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0022-5347(17)42717-0","article-title":"Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients","volume":"139","author":"Dykstra","year":"1988","journal-title":"J Urol"},{"issue":"3 Pt 1","key":"10.1016\/j.surge.2022.09.004_bib26","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0022-5347(05)67283-7","article-title":"Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results","volume":"164","author":"Schurch","year":"2000","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.surge.2022.09.004_bib27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.21037\/tau.2016.12.05","article-title":"Use of botulinum toxin for voiding dysfunction","volume":"6","author":"Eldred-Evans","year":"2017","journal-title":"Transl Androl Urol"},{"issue":"6","key":"10.1016\/j.surge.2022.09.004_bib28","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/mds.870120627","article-title":"DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1","volume":"12","author":"Sampaio","year":"1997","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.surge.2022.09.004_bib29","first-page":"459","article-title":"Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia","volume":"72","author":"Ranoux","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.surge.2022.09.004_bib30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0022-3565(25)31908-7","article-title":"Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction","volume":"212","author":"Simpson","year":"1980","journal-title":"J Pharmacol Exp Therapeut"},{"issue":"6","key":"10.1016\/j.surge.2022.09.004_bib31","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/j.1464-410X.2003.04714.x","article-title":"Botulinum toxin and its applications in the lower urinary tract","volume":"93","author":"Harper","year":"2004","journal-title":"BJU Int"},{"issue":"5773","key":"10.1016\/j.surge.2022.09.004_bib32","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1123654","article-title":"SV2 is the protein receptor for botulinum neurotoxin A","volume":"312","author":"Dong","year":"2006","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.surge.2022.09.004_bib33","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.eururo.2012.01.046","article-title":"Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action","volume":"61","author":"Coelho","year":"2012","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.surge.2022.09.004_bib34","first-page":"CD005493","article-title":"Botulinum toxin injections for adults with overactive bladder syndrome","author":"Duthie","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.surge.2022.09.004_bib35","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.eururo.2005.12.010","article-title":"Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity","volume":"49","author":"Apostolidis","year":"2006","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.surge.2022.09.004_bib36","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1046\/j.1464-410X.2003.04312.x","article-title":"A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity","volume":"92","author":"Harper","year":"2003","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.surge.2022.09.004_bib37","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.urology.2004.09.001","article-title":"Botulinum toxin: a new dimension in the treatment of lower urinary tract dysfunction","volume":"65","author":"Sahai","year":"2005","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.surge.2022.09.004_bib38","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/01.ju.0000169480.43557.31","article-title":"A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin","volume":"174","author":"Popat","year":"2005","journal-title":"J Urol"},{"issue":"9","key":"10.1016\/j.surge.2022.09.004_bib39","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1056\/NEJM200003023420918","article-title":"Treatment of neurogenic incontinence with botulinum toxin A","volume":"342","author":"Schurch","year":"2000","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.surge.2022.09.004_bib40","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/01.ju.0000162035.73977.1c","article-title":"Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study","volume":"174","author":"Schurch","year":"2005","journal-title":"J Urol"},{"issue":"9","key":"10.1016\/j.surge.2022.09.004_bib41","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s12325-013-0054-z","article-title":"OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology","volume":"30","author":"Ginsberg","year":"2013","journal-title":"Adv Ther"},{"issue":"8","key":"10.1016\/j.surge.2022.09.004_bib42","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/nau.22376","article-title":"OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity","volume":"32","author":"Rovner","year":"2013","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"10.1016\/j.surge.2022.09.004_bib43","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.juro.2007.01.130","article-title":"Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial","volume":"177","author":"Sahai","year":"2007","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.surge.2022.09.004_bib44","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","article-title":"Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial","volume":"184","author":"Dmochowski","year":"2010","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.surge.2022.09.004_bib45","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.surge.2022.09.004_bib46","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.surge.2022.09.004_bib47","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.juro.2016.03.146","article-title":"Durable efficacy and safety of long-term OnabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of a 3.5-year study","volume":"196","author":"Nitti","year":"2016","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.surge.2022.09.004_bib48","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2011.12.011","article-title":"Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates","volume":"61","author":"Dowson","year":"2012","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.surge.2022.09.004_bib49","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/bju.13025","article-title":"Patient experience and satisfaction with Onabotulinumtoxin A for refractory overactive bladder","volume":"116","author":"Malde","year":"2015","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.surge.2022.09.004_bib50","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2217\/cer-2018-0079","article-title":"Cost-effectiveness of overactive bladder treatments: from the US payer perspective","volume":"8","author":"Murray","year":"2019","journal-title":"J Comp Eff Res"}],"container-title":["The Surgeon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1479666X22001147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1479666X22001147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:17:43Z","timestamp":1761488263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1479666X22001147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1479666X22001147"],"URL":"https:\/\/doi.org\/10.1016\/j.surge.2022.09.004","relation":{},"ISSN":["1479-666X"],"issn-type":[{"type":"print","value":"1479-666X"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The translational implications of the science behind the overactive bladder and the role of OnabotulinumtoxinA","name":"articletitle","label":"Article Title"},{"value":"The Surgeon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.surge.2022.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier Ltd on behalf of Royal College of Surgeons of Edinburgh (Scottish charity number SC005317) and Royal College of Surgeons in Ireland. All rights reserved.","name":"copyright","label":"Copyright"}]}}